The results of three randomized trials of beta-carotene supplementation for the prevention of lung cancer among smokers are in contradiction to a large body of epidemiologic evidence for the reduction of risk of lung cancer among smokers with higher intake and/or higher serum levels of beta-carotene. Complicating this issue are widely noted negative associations between tobacco use and intake or serum levels of beta-carotene. Although observational studies attempt to control for reported smoking histories, the accuracy of self-reported smoking is uncertain; correlations as low as 0.5 between reported and true smoking exposure are not inconsistent with studies of biomarkers of cigarette exposure. The authors developed a simple statistical model for random errors in reported smoking (relative to true tobacco exposure) and assumed a modest (inverse) relation between true tobacco exposure and serum beta-carotene. Calculations from this model, combined with a model for lung cancer contemplated by Doll and Peto (J Epidemiol Community Health 1978;78:303-13), suggest that biases in assessment of smoking exposure between smokers with low versus high beta-carotene intake may plausibly explain much or all of the observed protective effect of high beta-carotene levels. Appropriate cohort studies of lung cancer in smokers, utilizing biomarkers of smoking, are needed and are presently ongoing. Am J Epidemiol 2002;155:622-8. beta carotene; lung neoplasms; measurement error; smoking
The failure of three prospective randomized trials (1) (2) (3) to find beneficial effects of beta-carotene supplementation on the risk of lung cancer among smokers was unexpected, given the consistent association in observational studies of low beta-carotene levels with elevated risk of lung cancer among smokers.
In their report on the results of the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study, Albanes et al. (2) discussed three possible explanations of this apparent paradox: 1) that serum levels and "usual" diet represent longterm exposure to beta-carotene and that effects on risk may be different from that of short-term exposure; 2) that betacarotene measured in blood or estimated from dietary intake may be acting as a marker for other correlated intakes that may, in fact, be protective; 3) that high beta-carotene intake or serum concentrations are general indicators of other beneficial dietary or protective lifestyle practices or are inversely associated with exposures to "harmful or carcinogenic factors." In this paper we discuss the possibility that the harmful factor in explanation 3 was, in fact, tobacco itself. Specifically we consider here the possibility that low beta-carotene levels may simply serve as a marker for higher than reported exposure to tobacco.
Several studies have reported that beta-carotene intakes (4 -8) and/or serum levels of beta-carotene (5) are negatively associated with reports of current smoking levels. Thus, at least to some extent, reductions in beta-carotene appear to act as a biomarker for smoking. All observational studies that found protective effects of beta-carotene on risk of lung cancer in smokers controlled for reported smoking history. However, because the metric of smoking exposure that is biologically relevant to lung cancer risk is undoubtedly less than perfectly correlated with reported numbers of cigarettes used per day, distortions in the beta-carotene effect due to residual confounding remain a distinct possibility. In this paper we outline the issues involved in evaluating the magnitude of potential distortions using relevant statistical models for residual confounding.
Several authors have suggested that residual confounding of beta-carotene intake with true smoking exposure may have induced the apparent protection afforded to smokers with high intake of beta-carotene. Henderson et al. (9) discussed the difficulty of interpreting beta-carotene effects given their findings that beta-carotene intake was lower in heavy smokers than in light smokers. Marshall and Hastrup (10) performed an extensive analysis of the extent of residual confounding expected in epidemiologic settings when a very strong confounder exists and specifically discussed the issues involved in joint analyses of beta-carotene, smoking, and lung cancer. This paper is an expansion of these previous discussions; in particular, we both elaborate and refine the approach of Marshall and Hastrup to deal with the following: evidence from studies of smoking biomarkers that may limit the possible magnitude of random errors in self-reports of current smoking; relative risk models for lung cancer as a function of observed smoking that are preferred based upon epidemiologic data; and an expansion of the models used for the relation between self-reports of smoking and true exposure to allow for the quite different effects of "classical" versus "Berkson" error in smoking self-reports. More discussion of this last issue is given below.
RESIDUAL CONFOUNDING AS AN EFFECT OF MEASUREMENT ERROR
Distortion of the joint relation between a disease outcome and covariates is one of the effects of random measurement error (10 -12) . Suppose that beta-carotene intake actually has no effect upon the risk of lung cancer, but that it is negatively correlated with the biologically relevant true exposure that we imagine to be only imperfectly correlated with reported smoking level. If true exposure were known for subjects in an epidemiologic study, then joint analyses would give an unbiased estimate of no effect for the influence of beta-carotene intake or serum levels on lung cancer risk conditional upon lung dose. If, however, lung dose is imperfectly measured (using reported cigarettes per day), then beta-carotene would remain somewhat negatively correlated with true lung dose conditional on reported smoking level. Beta-carotene would appear protective because groups of smokers with the same reported levels of smoking but different true lung doses would tend also to have different levels of beta-carotene.
A model for residual confounding
We adopt for illustrative purposes a simple multivariate model incorporating the following:
1. a bivariate lognormal distribution between true lung dose and reported smoking. True lung dose is standardized to units equivalent to cigarettes/day, and the marginal mean of true lung dose is taken as equal to the mean of reported smoking. One "cigarette" of true lung dose is the value that is on average dispensed by consumption of one cigarette, where the averaging is over the population of smokers. 2. a linear relation between the log of serum beta-carotene and (the arithmetic value of) true lung dose. This is similar to that used for the data analysis by Stryker et al. (5) . 3. a model for the relative risk of lung cancer in smokers.
We focus upon the relation described by Doll and Peto (13 (14) . We parameterize our model for reported smoking so that the median of reported smoking is equal to 20 cigarettes per day and so that 95 percent of smokers report between 5 and 60 cigarettes.
The following relation between the log of true lung dose, X, and the log of reported smoking, Z, is assumed:
Here Z is the mean of the log of reported smoking, and e is a random variable with mean zero and variance e 2 . The choices of b and e 2 determine the measurement error model. We note that if b ϭ 1 then this model corresponds to a so-called Berkson error model in which the log true dose is distributed symmetrically around log reported smoking as
Choosing b to be equal to the reliability coefficient
leads to the classical error model in which (log) reported smoking is distributed symmetrically around log true dose as
(See Appendix.) A Berkson error model is appropriate if it is believed that smokers reported cigarette intake accurately but that true lung dose was influenced by other factors, such as the number of puffs, depth of inhalation, and so on, that varies from smoker to smoker. A classical model is appropriate if random errors in the reported intakes are believed to be of overriding importance. By varying b we produce three models, a Berkson, a classical, and an intermediate variant, which we term the "mixed" model. In the mixed error model, a Berkson relation between true lung dose and true cigarette consumption and a classical error relation between reported smoking and true cigarette intake are both assumed and are assumed to have equal error variances. The error model (equation 1) describes a multiplicative relation between errors in reported smoking and true lung dose. We regard a multiplicative model as intuitively reasonable, because large true exposures are likely to have larger reporting errors than small values. Our purpose in exploring the general form (equation 1) of the measurement error model is to ensure, by varying b, that our results are not highly dependent upon subtleties of our modeling assumptions. between reported smoking and true lung dose, a value crucial to all that follows. Various studies describe associations of self-reported smoking with biomarkers including blood, urine, salivary or hair levels of nicotine or cotinine, blood thiocyanate or carboxyhemoglobin, and carbon monoxide expiration, with cotinine generally found to be the most sensitive (15) (16) (17) (18) . Correlations for cotinine ranged from 0.40 to 0.70 in various studies (17, 19 -23) . We consider two models: first, one in which the correlation between true lung dose and reported smoking, R z,x , equals 0.55 (the median of the correlations with cotinine measurements in the studies cited above); the second sets this correlation to 0.85, which we consider to be a very high value for the validity of a self-reported exposure. We denote those models with R z,x ϭ 0.55 as large error models and R z,x ϭ 0.85 as small error models.
Correlation between log beta-carotene and true lung dose. Although few studies directly examine the correlations between beta-carotene and reported smoking, reduced beta-carotene intake or serum levels in smokers versus nonsmokers and in heavy smokers versus light smokers are very evident (4 -8) . We assume a relatively weak negative correlation, R B,x ϭ Ϫ0.25, between log beta-carotene and true lung dose. Note that the correlations between reported smoking and (log) serum beta-carotene are attenuated by measurement errors compared with the true association. We have the convenient relation that for any of our error models
Corr͑log beta-carotene, reported smoking͒ ϭ Corr͑log beta-carotene, true lung dose͒ ϫ Corr͑reported smoking, true lung dose͒.
Under the large error model, a true correlation of Ϫ0.25 yields an observed correlation of Ϫ0.14, which is not implausible compared with the reports cited above. Reasons for negative correlations include a general tendency for smokers to have poor diets (7-9), perhaps as a direct effect of tobacco intake upon the perceived tastefulness of fruits and vegetables, and (for serum levels) a direct action of cigarette smoke on beta-carotene levels (24) .
Models for risk of lung cancer
Doll and Peto (13) assess the dose-response relation between smoking and lung cancer using careful age-specific comparisons of subjects who began smoking at approximately the same age and continued smoking throughout follow-up. Their model for the relative risk (RR) of lung cancer mortality may be written as
We use this model as well as a linear model 
cigarettes/day, is actually lower (RR ϭ 50) than on the self-report scale (RR ϭ 121). This somewhat unusual feature of the Berkson model is due to the fact that the average value, E(x͉z), of true dose, x, given observed dose, z, is higher than z on the arithmetic scale. The mixed model is intermediate in the degree of resulting attenuation (relative risk of 144 at true x ϭ 60 cigarettes/day compared with 121 on the observed dose scale).
MATERIALS AND METHODS
For each choice of b and e 2 in model 1, we can find relative risk models, RR(x), on the true dose scale x that correspond to models 2 and 3 on the scale of z and that are functions of one or both of x 1/b and x 2/b , respectively. We integrate RR(x) over the conditional distribution, f(x͉z, B), of x given z and B. To compare the lung cancer risk of two smokers with the same z but different beta-carotene levels B 1 and B 2 , we form the new relative risk ratio
Studies in smokers typically compare the risk of lung cancer of subjects with "low" values of beta-carotene with those of smokers with "high" values of beta-carotene. In our calculations of RR we do the same thing, picking low values of B to be the average for the lowest quartile of beta-carotene and high values to be the average in the highest quartile. Details of the relevant calculations are given in the Appendix. High values of RR indicate important residual confounding between beta-carotene and true lung dose in observational studies. Many observational studies have found the risks for smokers with low levels of beta-carotene to be about twice the risks for those with high levels of betacarotene intake or serum measurements. If RR in equation 4 approaches 2, then we argue that these observational findings may in fact be purely an artifact of errors in the measurement of smoking. Table 1 gives the risk ratio RR expected between smokers with low and high beta-carotene intake, conditional on the same level of reported smoking, according to the following factors:
RESULTS
1. the choice of b in the measurement error model 1.
Three choices corresponding to the Berkson, classical, and mixed models are given. 2. the degree of correlation, R z,x , between true lung dose and reported smoking, which itself is dependent on b and e 2 in model 1. 3. the choice of risk model for lung cancer as being either linear-quadratic (model 2) or linear (model 3). 4. whether reported smoking z is taken to be a continuous or a grouped variable (with three categories) in the conditioning.
In all cases the calculations are performed under the assumption that the correlation, R B,x , between the true lung dose and the log beta-carotene level is equal to Ϫ0.25.
In table 1 a combination of the linear-quadratic model for risk with the high-error models for reported smoking leads to risk ratios, RR, which range from approximately 1.8 to 2.3 depending upon whether a Berkson, classical, or mixed measurement error model is chosen for the relation between true and reported smoking; the risk ratio is slightly higher for the classical and mixed models than it is for the Berkson model. Using the linear model lowers the risk ratio, with RR now between 1.3 and 1.6; again RR is slightly higher for the classical and mixed models than for the Berkson model. As expected, the results are quite dependent upon whether the high or low error measurement model is chosen: The maximum risk ratio for the low error model is 1.2 for the quadratic risk model using mixed or classical errors.
DISCUSSION
Cigarette smoking is by far the most important cause of lung cancer, and the dose-response relation between true smoking level and lung cancer risk may be even stronger than that which can be observed using self-reports of smoking. Because of the extraordinary strength of the doseresponse relation between true exposure and risk, any variable such as beta-carotene that may be providing a modest amount of additional information about true exposure needs to be very carefully examined as a confounder before making conclusions about its own likely contribution to risk. This general point (that residual confounding is important) has been made repeatedly by statisticians (11, 12) and specifically by Marshall and Hastrup (10) in the case of beta-carotene's apparent protective effects. Our expanded discussion of this issue here is intended to reinforce the need to secure better data on the accuracy of the measurement of smoking and on the strength of the relation between betacarotene intake and smoking exposure.
In a recent account, Albanes (25) discounts the possibility that residual confounding could be at the root of observations of a protective effect of beta-carotene, indicating that most studies involved "adequate control" of smoking history and other known confounders. We disagree and believe that residual confounding must in fact be considered as an important candidate among potential explanations. Some epidemiologists dealing with cohort analyses evidently now also take this view. A recent report of a cohort study analysis (26) noted that careful control for self-reported cigarette exposure led to reductions in the apparent protective effect of beta-carotene intake and noted that the remaining protective effect seen may be indicative of confounding by unmeasured smoking characteristics.
In our modest correlation (R B,x ϭ Ϫ0.25), high measurement error (R z,x ϭ 0.55) model, the relative risk induced purely by residual confounding lies between 1.3 and 2.3 depending upon whether it is the linear or quadratic risk model and whether it is the Berkson model or classical error model that is used. Relative risks of this magnitude approach the levels seen for the apparent protective effect of beta-carotene in the observational studies of interest, so that most or all of the protective effects seen among smokers are plausibly due to residual confounding with tobacco given what we know (or don't know) today about the magnitude of random errors in smoking self-reports. The fact that our findings are only partly dependent upon whether the Berkson, classical, or mixed model is assumed for errors in self-reports satisfies us that our results are robust to the details of the measurement model used; this is true despite the profound differences in the degree of attenuation of the true smoking model induced by these three different error models. This points out a truism about exposure measurement error: that the loss of control of confounding variables, that is, residual confounding, is a more characteristic effect of random measurement error than is the well-known "bias toward the null" because the latter is primarily a feature of the classical measurement model. Our high error (R x,z ϭ 0.55) model is consistent with the literature regarding correlations between cotinine and selfreports only if we assume that cotinine is a nearly perfect reflection of true dose, an issue that is clearly open to dispute. Several studies indicate that cotinine, in particular, is associated with individual smoking behaviors (puffing, cigarette time) (27) , as well as total cigarettes (16), and may be more predictive of adverse health outcomes than is reported smoking (28, 29) . Nevertheless we recognize that the correlation between biomarkers and true lung dose is itself attenuated to some unknown degree by measurement error and that the high measurement error model would allow little play for this factor.
More careful examination of the relation between intake and serum levels of beta-carotene and reported levels of smoking in existing data sets is needed. One relevant reference is Stryker et al. (5) who reported a negative value for the slope of the bivariate regression of log beta-carotene consumption on cigarettes/day significant at the p ϭ 0.0004 level among 137 males (25 percent of whom were current smokers). This significance level corresponds to R ϭ Ϫ0.296 among the same number of subjects using Fisher's z transformation to do the hypothesis test. Although this correlation would be smaller in magnitude if restricted only to smokers, this aspect is counterbalanced by attenuation due to measurement errors in using reported smoking level rather than the biologically relevant true exposure. Given these considerations, we do not believe that a negative correlation between beta-carotene and true lung dose of the magnitude assumed in this paper (i.e., Ϫ0.25) is at all outside the range of plausibility. The risk ratios given in table 1 are quite dependent on the assumption of negative correlations this large; for example, for the classical model with high error, assuming this correlation to be equal to Ϫ0.15 instead of Ϫ0.25 reduces the risk ratio from 1.6 to 1.3 for the linear model. We note a very recent report (30) of a strongly significant inverse relation between systemic markers of inflammation and the serum beta-carotene level in both smokers and nonsmokers. Further examination of these sorts of data will also help in evaluating whether a correlation of Ϫ0.25 between the biologically relevant aspects of smoking exposure (such as those causing inflammation and presumably enhancing cancer induction and/or promotion) and serum beta-carotene is, in fact, reasonable.
Our calculations have been based upon the Doll and Peto (13) model in which it is the current smoking amount that affects the current risk of lung cancer, not total accumulated dose (pack-years) or duration of smoking. Duration of smoking must be dealt with carefully as a risk factor because it is confounded both with current age (a huge risk factor) and age at start (a potentially important risk factor). It is our own belief that studies that deal properly (by stratification) with these confounders, but still find that duration of smoking is much more predictive of risk than smoking amount is, may, in fact, have been especially subject to large errors in reported smoking.
To date there has been little or no work in observational studies of lung cancer controlling for biomarkers for smoking, and this would be very difficult to do in case-control studies. We are aware of a project at the Hawaii Cancer Research Center in Honolulu that will collect urine and serum samples at baseline, for prospective follow-up, for approximately 40,000 members of the Hawaii-Los Angeles multiethnic cohort study (31) . One of the aims of the lung cancer component of this study (L. Marchand, Principal Investigator) is to investigate the relation between lung cancer and cotinine and various markers of nutrition intake including beta-carotene utilizing the stored samples. Clearly a finding from this study that the protective effect of betacarotene is much weaker after conditioning on cotinine than when conditioning on reported levels of smoking would further implicate residual confounding as a cause of the beta-carotene effect seen in previous observational studies. On the other hand, if beta-carotene appeared protective after conditioning on cotinine, this could mean either that betacarotene is actually protective or that serum cotinine is simply a poor biomarker. However, this latter conclusion would be an important indirect argument in favor of the protective effect of beta-carotene. Because of measurement error attenuation, the high error models being relied on here are inconsistent with reports in the literature of correlations of Ն0.4 between cotinine and observed smoking unless cotinine is actually a very good biomarker for true exposure. Therefore, we regard the University of Hawaii work as likely to add considerably to the state of current knowledge about whether residual confounding is at the root of the apparent protective effects of beta-carotene. 
